PR Newswire Clinical TrialsOriginal article
Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures
ConferenceibezapolstatvancomycinfidaxomicinPositive
AI Analysis
Summary
Acurx announced a poster presentation at the International C. difficile Symposium showing ibezapolstat demonstrated superior in vitro kill kinetics against C. difficile and vancomycin-resistant Enterococcus compared to vancomycin and fidaxomicin standards of care.
Clinical Trial Data
Importance:4/10
Sentiment:
0.60
in vitro studyC. difficileibezapolstatcomparative efficacyposter presentationICDS symposium
Read the original article
Published by PR Newswire Clinical Trials on September 14, 2026 12:01 PM